Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $137.2 million.

  • Avidity Biosciences' Accumulated Expenses rose 651.95% to $137.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.2 million, marking a year-over-year increase of 651.95%. This contributed to the annual value of $64.7 million for FY2024, which is 351.52% up from last year.
  • Latest data reveals that Avidity Biosciences reported Accumulated Expenses of $137.2 million as of Q3 2025, which was up 44.02% from $95.2 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Accumulated Expenses peaked at $137.2 million during Q3 2025, and registered a low of $2.7 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $35.2 million, with a median of $12.8 million in 2024.
  • Data for Avidity Biosciences' Accumulated Expenses shows a peak YoY skyrocketed of 651.95% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Avidity Biosciences' Accumulated Expenses stood at $8.9 million in 2021, then rose by 25.17% to $11.2 million in 2022, then rose by 28.11% to $14.3 million in 2023, then soared by 351.52% to $64.7 million in 2024, then spiked by 651.95% to $137.2 million in 2025.
  • Its Accumulated Expenses was $137.2 million in Q3 2025, compared to $95.2 million in Q2 2025 and $12.8 million in Q1 2025.